FDA公布浙江临海天宇药业483检查报告,列7项观察
FDA 483:浙江临海天宇药业有限公司
FDA公布对浙江临海天宇药业有限公司(FEI 3013345425)的483检查报告,2023年9月11日至15日检查后列7项观察。第4项观察记录QC复核员连续勾选约5份分析批记录、六个批次共18份检测记录,期间未打开色谱软件;第1项观察指清洁保持时间研究未就不同产品轮换生产提供科学论证。报告另记录该公司HPLC与GC检测使用多达五种软件,复核时未对所有电子检测数据充分核对。
近日,FDA 公布了对浙江临海天宇药业有限公司(浙江省台州市临海市头门港经济开发区东海第五大道15号,FEI 3013345425)的483检查报告,检查5天,列7项观察,涵盖车间到实验室:管道保温层破损、地面有红褐色残留和积水;清洁保持时间研究没考虑不同产品轮换生产;11个批次因杂质超标销毁,根本原因找到了却不做 CAPA;OOS 根因反复写成“化验员没换手套”;用于稳定性考察的方法不具备稳定性指示能力;五套色谱软件并存、数据不做核对。
最刺眼的一处在第4项:QC 复核员连续勾了约5份分析批记录、六个批次共18份检测记录,期间色谱软件一次没打开——他称一小时前在另一个房间看过。检查员把这句话原样写进了报告。
图1 FDA 483 原件第1页(FEI 3013345425,2023年9月15日签发,共9页)
Inspection Details
检查基本信息
Firm / 企业
Linhai Tianyu Pharmaceutical Co., Ltd. 临海天宇药业有限公司
Address / 地址
No. 15 Donghai 5th Ave., Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone(浙江省台州市临海市头门港经济开发区东海第五大道15号)
City / 城市
Taizhou, Zhejiang 317016 China(中国浙江台州,317016)
FEI Number / FEI 号
3013345425
Dates of Inspection / 检查日期
2023年9月11日–9月15日(周一至周五)
Type Establishment Inspected / 受检设施类型
Active Pharmaceutical Ingredient and Intermediate Manufacturer(原料药与中间体生产企业)
Issued To / 收件人
Mr. Tu Yongjun, President(屠勇军,董事长)
District Office / 地区办公室
ORA OPQO HQ, Room #2032, 12420 Parklawn Drive, Rockville, MD 20857
Issued / 签发
2023年9月15日 检查员:Arsen Karapetyan(DDC);Anders W. Evenson
说明:原件未印法规条款号。七项观察的标题分别对应 21 CFR 211.67(b)、211.67(a)、211.192、211.194(a)、211.166(a)、211.68(b)、211.22(d),属编者对应,见文末译注①。
OBSERVATION 1
观察1:设备清洁与维护的书面程序(211.67(b))
Written procedures are deficient for the cleaning and maintenance of equipment used in the manufacturing, processing, packing, or holding of a drug substance.
用于原料药生产、加工、包装或贮存的设备,其清洁与维护的书面程序存在缺陷。
Specifically,
具体而言,
Your firm's clean hold time study and evaluation report (Confirmation report on the validity of the clean retention time of the crude (b)(4) production equipment GP-EV-PR-3-211203; Evaluation Report on Reasonableness of CHT of (b)(4) Area Equipment GR-EV-PR-3-220805) that are applicable for drug substances and intermediates, including (b)(4) (b)(4) conclude a (b)(4) clean hold time in (b)(4) following a (b)(4) clean. Your firm's Equipment Cleaning Management Procedure SMP-PR-011 requires a (b)(4) clean for (b)(4) beyond this (b)(4) hold time that is valid for (b)(4). Your firm's Cleaning Management Procedure (SMP-PR-011) and clean hold time study and evaluation (GP-EV-PR-3-211203, GP-EV-PR-3-220805) are deficient because they do not include adequate scientific justification for the (b)(4) clean hold time following a (b)(4) clean after (b)(4) (b)(4) clean. For example, we reviewed Equipment Operational Logbooks FOM-GDL-035-01 for 2022.05.09-2022.08.10 and 2022.08.18-2022.08.28 for (b)(4) (b)(4) 215 in Workshop (b)(4). On July 4, 2022, your firm completed a (b)(4) clean after a (b)(4) production campaign of (b)(4) on (b)(4) (b)(4) per your firm's Cleaning Management Procedure (SMP-PR-011). On August 16, 2022, your firm began a (b)(4) batch production campaign for (b)(4) an intermediate used in the manufacturing of drug substance (b)(4) for the China and Europe market. Your firm has no scientific justification that confirms a (b)(4) clean following a (b)(4) clean hold time is sufficient on (b)(4) equipment used between production campaigns of (b)(4) different products.
贵公司的清洁保持时间研究与评估报告,即《粗品 (b)(4) 生产设备 GP-EV-PR-3-211203 清洁保持时间有效性确认报告》与《(b)(4) 区域设备 GR-EV-PR-3-220805 清洁保持时间(CHT)合理性评估报告》,适用于原料药和中间体(包括 (b)(4) (b)(4)),其结论为:在 (b)(4) 清洗之后,(b)(4) 内具有 (b)(4) 的清洁保持时间。贵公司《设备清洁管理程序》SMP-PR-011 要求:超过这一 (b)(4) 保持时间后,须对 (b)(4) 进行 (b)(4) 清洗,该保持时间对 (b)(4) 有效。贵公司《清洁管理程序》(SMP-PR-011)与上述清洁保持时间研究及评估(GP-EV-PR-3-211203、GP-EV-PR-3-220805)存在缺陷,因其未为 (b)(4) (b)(4) 清洗之后的 (b)(4) 清洁保持时间提供充分的科学论证。例如,我们查阅了 (b)(4) 车间 (b)(4) (b)(4) 215 的《设备运行记录》FOM-GDL-035-01(2022.05.09–2022.08.10 与 2022.08.18–2022.08.28)。2022年7月4日,贵公司按《清洁管理程序》(SMP-PR-011)完成了 (b)(4) (b)(4) 上 (b)(4) 生产批次之后的 (b)(4) 清洗。2022年8月16日,贵公司开始了 (b)(4) 批次的生产,用于 (b)(4)——一种用于生产供中国和欧洲市场原料药 (b)(4) 的中间体。贵公司没有科学论证可以确认:在生产批次之后,对 (b)(4) 设备做一次 (b)(4) 清洗,其后的 (b)(4) 清洁保持时间,对 (b)(4) 个不同产品是充分的。
OBSERVATION 2
观察2:设施与设备维护(211.67(a))
Facilities and equipment used in the manufacturing of drug substances are not adequately maintained.
用于原料药生产的设施与设备,未得到充分维护。
Specifically,
具体而言,
During our facility walk-through on 9/11/2023, we observed the following conditions in Workshops (b)(4) and (b)(4) that are used for drug substance manufacturing of (b)(4) and other drug substances and intermediates intended for the U.S. market:
2023年9月11日的设施巡查中,在 (b)(4) 和 (b)(4) 车间观察到以下情况——这些车间用于生产 (b)(4) 以及其他供美国市场的原料药和中间体:
Workshop (b)(4):
(b)(4) 车间:
(b)(4) 315 with three ~2 feet segments of broken pipe insulation laying near utility pipes that connect to the (b)(4) station and (b)(4) tank
(b)(4) 315:连接 (b)(4) 工位与 (b)(4) 罐的公用工程管道附近,地面上有三段约2英尺长的破损管道保温层
(b)(4) 318 with multiple reddish/brown areas on the ground and a puddle of water under the utility pipes that connect to the (b)(4) station and the (b)(4) tank
(b)(4) 318:地面有多处红褐色区域,连接 (b)(4) 工位与 (b)(4) 罐的管道下方有一滩积水
(b)(4) 322 with reddish/brown areas surrounding utility pipes that run through the floor and connect to the (b)(4) station and (b)(4) tank
(b)(4) 322:穿过地面、连接 (b)(4) 工位与 (b)(4) 罐的管道周围,有大片红褐色区域
Area between (b)(4) 214 and (b)(4) 215 with 1) a (b)(4) ~3-feet by 2-feet by 2-inch pan-like item placed under the utility pipes that connect to the (b)(4) station and (b)(4) tanks 2) a ~2 feet by 1 foot reddish/brown area of peeling floor under utility pipes that connect to the (b)(4) station 3) a drooping clear coil with reddish/brown residue that connects to utility pipes that connect to the (b)(4) station
(b)(4) 214 与 (b)(4) 215 之间的区域:1) 连接 (b)(4) 工位与 (b)(4) 罐的管道下方,放置了一个约3英尺×2英尺×2英寸的盘状物件;2) 连接 (b)(4) 工位的管道下方,有一块约2英尺×1英尺的地面剥离区,呈红褐色;3) 一根下垂的透明软管带红褐色残留,与通向 (b)(4) 工位的管道相连
(b)(4) 217 with a drooping clear coil with reddish/brown residue that carries (b)(4) to utility pipes that connect to the (b)(4) station and (b)(4) tank
(b)(4) 217:一根下垂的透明软管带红褐色残留,将 (b)(4) 输送至连接 (b)(4) 工位与 (b)(4) 罐的管道
Workshop (b)(4):
(b)(4) 车间:
(b)(4) with a detached floor area of ~1 foot by 1 foot with reddish/brown residue directly next to the (b)(4) tank with a pipe running through it
(b)(4):紧邻带有穿管的 (b)(4) 罐处,有一块约1英尺×1英尺的地面脱落,带红褐色残留
Workshop (b)(4):
(b)(4) 车间:
(b)(4) 416 with (b)(4) insulation on the outside of the (b)(4) station while production of (b)(4) (b)(4) batch (b)(4) was occurring
(b)(4) 416:在生产 (b)(4) (b)(4) 批次 (b)(4) 期间,(b)(4) 工位外部仍带 (b)(4) 保温层
Your firm uses Equipment Maintenance Management Procedure SMP-EN-003 that requires (b)(4) patrol and documentation of facilities and equipment used in the production of drug substances in Workshops (b)(4) (b)(4) and other workshops. Your firm did not adequately document (b)(4) (b)(4) patrols nor the inadequate status of equipment and pipelines in Workshop (b)(4) within the Equipment Inspection Record FOM-SMP-EN-003-03.03 for Workshop (b)(4) that is required per the Equipment Maintenance Management Procedure SMP-EN-003.
贵公司执行《设备维护管理程序》SMP-EN-003,要求对 (b)(4) (b)(4) 及其他车间中用于原料药生产的设施与设备进行 (b)(4) 巡检并记录。但贵公司未在《设备检查记录》FOM-SMP-EN-003-03.03((b)(4) 车间)中充分记录 (b)(4) (b)(4) 巡检,也未记录 (b)(4) 车间设备与管道的不合格状态——而该记录正是 SMP-EN-003 所要求的。
图2 原件第2页:第2项观察的车间巡查记录
OBSERVATION 3
观察3:调查记录缺结论与跟踪(211.192)
Written records of investigation into unexplained discrepancies and the failure of a batch or any of its components to meet specification do not always include the conclusions and follow-up.
对无法解释的差异、以及批次或其任何组分不符合质量标准的调查,其书面记录并不总是包含结论与后续跟踪。
Specifically,
具体而言,
Investigations initiated and performed by your Quality Unit in response to Out of Specification results, laboratory events, and market complaints related to intermediates and API manufactured by your firm are not always scientifically sound or comprehensive with respect to root cause determination. Additionally, Corrective Action/Preventive Action (CAPAs) as a result of investigations are not always comprehensive to address root causes documented to have been performed. For example:
贵公司质量部门针对本公司生产的中间体和原料药的不合格(OOS)结果、实验室事件与市场投诉所发起和实施的调查,在根本原因判定方面并不总是科学合理或全面。此外,调查产生的纠正与预防措施(CAPA)也不总能全面覆盖已记录的根本原因。例如:
A. -On or around 01/14/2021, OOS-205301-21001 was initiated for intermediate (b)(4) (b)(4) batch number (b)(4) (b)(4) (intermediate for (b)(4) (b)(4) drug substance) for other single impurity with results as (b)(4) % and (b)(4) % versus specification of NMT (b)(4) %. Your firm's investigation determined the root cause to be "the tester did not change gloves after testing the (b)(4) solution and directly prepared the (b)(4) sample solution, resulting in contamination".
A. 2021年1月14日前后,针对中间体 (b)(4) (b)(4) 批号 (b)(4)(为 (b)(4) 原料药 (b)(4) 的中间体)启动 OOS-205301-21001:其他单一杂质结果为 (b)(4)% 与 (b)(4)%,标准为不超过 (b)(4)%。贵公司调查判定根本原因为“化验员测试 (b)(4) 溶液后未更换手套,直接配制 (b)(4) 样品溶液,导致污染”。
-On or around 01/21/2021, OOS-10501-21001 was initiated for drug substance (b)(4) (b)(4) batch number (b)(4) (b)(4) for (b)(4) impurity with result as (b)(4) ppb versus specification of LOD (b)(4) ppb. Your firm's investigation determined the root cause to be "the tester did not wear gloves when weighing back, returning the control and transferring the test solution, resulting in contamination of the test solution".
2021年1月21日前后,针对原料药 (b)(4) (b)(4) 批号 (b)(4) 启动 OOS-10501-21001:(b)(4) 杂质结果为 (b)(4) ppb,标准为检出限 (b)(4) ppb。调查判定根本原因为“化验员在回称、归还对照品和转移测试溶液时未戴手套,导致测试溶液污染”。
-On or around 06/08/2021, OOS-10501-21003 was initiated for intermediate (b)(4) (b)(4) (intermediate for (b)(4) (b)(4) drug substance), batch number (b)(4) (b)(4) for test item (b)(4) (b)(4) with result as (b)(4) ppm versus specification of NMT (b)(4) ppm. Your firm's investigation determined the root cause to be "the inspector did not change his gloves when testing (b)(4) resulting in some bottle caps being contaminated with (b)(4)".
2021年6月8日前后,针对中间体 (b)(4) (b)(4)((b)(4) 原料药 (b)(4) 的中间体)批号 (b)(4) 启动 OOS-10501-21003:检测项目 (b)(4) (b)(4) 结果为 (b)(4) ppm,标准为不超过 (b)(4) ppm。调查判定根本原因为“检验员在检测 (b)(4) 时未更换手套,导致部分瓶盖被 (b)(4) 污染”。
-On or around 01/01/2022, OOS-10501-22001 was initiated for drug substance (b)(4) (b)(4) batch number (b)(4) (b)(4) 6-month accelerated stability test for (b)(4) impurity with result as (b)(4) ppb versus a specification of LOD (b)(4) ppb. Your firm's investigation determined the root cause to be "the bottle cap used for the test did not differentiate between the use of samples and controls, and the tester got the (b)(4) contaminated bottle cap, resulting in the test solution being contaminated with (b)(4)".
2022年1月1日前后,针对原料药 (b)(4) (b)(4) 批号 (b)(4) 的6个月加速稳定性试验启动 OOS-10501-22001:(b)(4) 杂质结果为 (b)(4) ppb,标准为检出限 (b)(4) ppb。调查判定根本原因为“检测所用瓶盖未区分样品与对照的使用,化验员拿到了被 (b)(4) 污染的瓶盖,导致测试溶液被 (b)(4) 污染”。
B. Starting from 04/01/2021 to 07/07/2022, your firm has initiated 2 OOT and 7 OOS investigations for 11 batches with respect to intermediate product (b)(4) for test specifications for any individual impurity (NMT (b)(4) %) and/or total impurities (NMT (b)(4) %). All batches involved were said to be destroyed as a result. Subsequent investigations performed by your firm's QC and R&D units have resulted in the identification of a root cause for formation of the impurity, however no adequate CAPA has been implemented to address this root cause. Per your firm's personnel, current action plan, should another OOS occur, is to destroy the batch.
B. 2021年4月1日至2022年7月7日,就中间体产品 (b)(4) 的单项杂质(不超过 (b)(4)%)和/或总杂质(不超过 (b)(4)%)标准,贵公司对11个批次启动了2项 OOT 与7项 OOS 调查。涉事批次据称已因此全部销毁。贵公司 QC 与研发部门后续调查已确定杂质形成的根本原因,但未实施充分的 CAPA来解决这一根本原因。据贵公司人员称,当前行动计划是:如果再出现 OOS,就销毁批次。
C. During our review of your Empower 3 chromatography software, interrupted sequences were observed, which generated "Data Incomplete" chromatographic data. Your firm documented these interrupted injections due to a power outage via investigation no. DR-3-22003R, dated 02/27/2022, showing that no chromatograms had been generated for (b)(4) (b)(4) drug substance batch numbers (b)(4) (b)(4). However, during the investigation, the interrupted sample injections were not adequately documented and/or investigated, in that your firm did not verify the incomplete data to evaluate if the interrupted sequence chromatogram for abnormalities.
C. 在审查贵公司 Empower 3 色谱软件时,发现存在序列中断,产生了“数据不完整”的色谱数据。贵公司通过2022年2月27日的调查 DR-3-22003R 将上述中断进样记录为停电所致,显示 (b)(4) (b)(4) 原料药批号 (b)(4) (b)(4) 未生成色谱图。但在调查中,中断的样品进样未得到充分记录和/或调查,贵公司未对不完整数据进行核实,以评估中断序列的色谱图是否存在异常。
D. Complaint No. CH-3-23004, dated 02/20/2023 was initiated due to customer complaint (b)(4) OOS results for 7 batches of (b)(4) (b)(4) intermediate shipped to your customer. This intermediate is used for the manufacture of (b)(4) (b)(4) API, potentially intended for the U.S. Market. Based on your firm's investigation, no issues were found, and the complaint was not justified. After your firm communicated the results of your findings to your customer, your customer replied that their quality unit had released these batches for use to manufacture. There was no adequate follow up by your firm to determine why these batches were released, specifically what the root cause of your customers investigation revealed. During our inspection, your firm re-initiated communication with your customer to determine your customers investigation results.
D. 2023年2月20日的投诉 CH-3-23004 源于客户投诉:发往该客户的7个批次 (b)(4) (b)(4) 中间体出现 (b)(4) OOS 结果。该中间体用于生产 (b)(4) (b)(4) 原料药,可能销往美国市场。按贵公司的调查,未发现问题,投诉不成立。贵公司将调查结果告知客户后,客户回复称其质量部门已放行这些批次用于生产。贵公司未充分跟进,以确定这些批次为何被放行,特别是客户调查所揭示的根本原因是什么。检查期间,贵公司重新与客户沟通,以获取其调查结果。
E. On or around 03/07/2019, 7 OOS investigations for 7 batches were initiated for intermediate (b)(4) for OOS results with respect to specification other individual impurity NMT (b)(4) %. Your firm's investigations resulted in root cause determination as a damaged (b)(4) (b)(4). Your firm's CAPA included replacing the damaged (b)(4) with a new (b)(4) and retesting. No consideration was given to the establishment of (b)(4) (b)(4) management and maintenance procedure as part of your investigation and CAPA.
E. 2019年3月7日前后,针对中间体 (b)(4) 就其他单一杂质标准(不超过 (b)(4)%)的 OOS 结果,对7个批次启动了7项 OOS 调查。调查判定根本原因为 (b)(4) (b)(4) 破损。CAPA 包括用新的 (b)(4) 更换破损件并复测。作为调查与 CAPA 的一部分,未考虑建立 (b)(4) 管理与维护程序。
For all OOS investigations performed by your firm, the assignable root cause was determined without performing hypothesis studies and without scientific justification.
对贵公司开展的所有 OOS 调查而言,可归因的根本原因,都是在未开展假设性研究、也没有科学论证的情况下判定的。
OBSERVATION 4
观察4:实验室记录(211.194(a))
Laboratory records are not completed contemporaneously and do not include complete data derived from all tests to assure compliance with established specifications and standards.
实验室记录未同步完成,且未包含为保证符合既定标准与规范而从所有检测中获得的完整数据。
Specifically,
具体而言,
A. Electronic and physical laboratory records data review are not completed contemporaneously by your QC reviewers. During our walkthrough of your QC laboratory data review room on 09/11/23, I observed your QC analyst/reviewer checking off boxes on a form titled "Checklist of Electronic Data" for approximately 5 analytical batch records for (b)(4) testing of (b)(4) API via Ion Chromatography test, one after another, without any software opened for review. In all, we counted approximately 18 analytical test records for six batches which the analyst confirmed to have performed during the observed review process from above. Your analyst stated that they had reviewed the electronic data on the software in another room approximately one hour before.
A. QC 复核人员的电子与纸质实验室记录数据复核,未同步完成。2023年9月11日,在 QC 实验室数据复核室巡查时,我观察到贵公司的 QC 分析员/复核员在一份题为“电子数据检查表”的表格上勾选,连续处理约5份分析批记录((b)(4) 原料药经离子色谱检测 (b)(4)),期间未打开任何软件进行复核。我们总计清点出六个批次约18份分析检测记录,分析员确认这些都是在上文所述的复核过程中完成的。该分析员称,大约一小时前,他已在另一个房间的软件上复核过这些电子数据。
B. Microbiology laboratory records and usage logbooks are not completed contemporaneously by your analysts. During our walkthrough of your microbiology laboratory, we observed a QC analyst filling out a form titled "Preparation and Use Records of Control Medium" for preparation of (b)(4) (b)(4) controlled media used for system suitability reference for testing of (b)(4) (b)(4) water. Items observed in the process of being filled out included, but not limited to, reagents used, quantity of reference media and (b)(4) water used, stirring to dissolve operations, dispensing into a bottle operation, and (b)(4) (b)(4) operations. Per your analyst, they had finished preparation of the (b)(4) controlled media prior to my arrival to the room.
B. 微生物实验室记录与使用台账,未由分析员同步完成。在微生物实验室巡查时,我们观察到一名 QC 分析员正在填写题为“对照培养基配制与使用记录”的表格,用于配制 (b)(4) (b)(4) 对照培养基——该培养基用作 (b)(4) (b)(4) 水检测的系统适用性对照。观察到的、正在填写的项目包括但不限于:所用试剂,对照培养基与 (b)(4) 水的用量,搅拌溶解操作,分装入瓶操作,以及 (b)(4) (b)(4) 操作。据该分析员称,在我进入该房间之前,他们已完成 (b)(4) 对照培养基的配制。
OBSERVATION 5
观察5:稳定性考察方案(211.166(a))
There is no written testing program designed to assess the stability characteristics of drug substances and intermediates.
没有为评估原料药和中间体的稳定性特征而设计的书面检测方案。
Specifically, the assay and related substance test methods for intermediate (b)(4) used for stability testing are not stability indicating, where they can detect the change with time in chemical, physical or microbiological properties of the intermediate drug substance so that the content of active ingredients and degradation products can be accurately measured without interference. As a result, the validity of the stability of the process cannot be verified, in that your firm is not able to monitor results during stability studies in order to assure safety, efficacy and quality for your intermediate drug substance.
具体而言,用于稳定性检测的中间体 (b)(4) 的含量与有关物质检测方法,不具备稳定性指示能力——即无法检测中间体原料药在化学、物理或微生物性质上随时间的变化,以致活性成分与降解产物的含量无法在不受干扰的情况下被准确测量。因此,工艺稳定性的有效性无法得到验证,贵公司无法在稳定性研究期间监测结果,以确保其中间体原料药的安全性、有效性和质量。
OBSERVATION 6
观察6:计算机系统控制(211.68(b))
Appropriate controls are not exercised over computers or related systems to assure that changes in quality control records are instituted only by authorized personnel.
未对计算机或相关系统实施适当控制,以确保质量控制记录的变更仅由授权人员进行。
Specifically,
具体而言,
GMP related computerized systems and equipment have not been validated/qualified to demonstrate the suitability of computer hardware and software to perform assigned tasks. Your firm appears to have performed Performance Verification and data integrity assessments for Empower 3 software, however the verification and assessments do not evaluate the consistent performance of the software/equipment over a specified period and operating environment. For example, during our review of your Empower 3 chromatography software, interrupted sequences were observed, which generated "Data Incomplete" chromatographic data. Your firm has not demonstrated full understanding of the different types of communication errors and circumstances which may lead to a "Data incomplete" or Bad Checksum/Data Missing chromatography considering the relationship between the Empower application and database server, Empower RDS servers, internet connection, Empower LAC/Es, and the instruments connected to LAC/Es. This discrepancy in your firm's ability to review, document, and investigate all electronic data is a gap in your Data Integrity Program.
GMP 相关的计算机化系统与设备未经验证/确认,以证明计算机硬件与软件适合执行指定任务。贵公司似乎已对 Empower 3 软件开展性能验证与数据完整性评估,但这些验证与评估并未评价软件/设备在特定期间和运行环境下的一致性能。例如,在审查贵公司 Empower 3 色谱软件时,发现序列中断,产生了“数据不完整”的色谱数据。贵公司尚未证明充分理解可能导致“数据不完整”或校验和错误/数据丢失色谱的不同类型通信错误与情形——这涉及 Empower 应用与数据库服务器、Empower RDS 服务器、互联网连接、Empower LAC/E,以及连接至 LAC/E 的仪器之间的关系。贵公司在审查、记录和调查所有电子数据方面的这一差距,是其数据完整性计划的缺口。
OBSERVATION 7
观察7:QC 职责与程序(211.22(d))
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
适用于质量控制部门的职责与程序,未形成书面文件并完全遵守。
Specifically,
具体而言,
Supervisory oversight over the laboratory electronic systems and data is deficient. Per your firm's data review procedure, Quality Control (QC) personnel perform review electronic test data for all analytical batch records using an approved review procedure and checklist for HPLC/GC network equipment. This review process does not appear to be adequate, in that all potential data generated during that specific review period for that product are not reviewed. For example, your firm utilizes up to five different software's for testing of intermediate and API products on HPLC and GC equipment, which include, Empower 3, OpenLab CDS, LabSolutions, MassHunter. There is no software dedicated to testing of a particular intermediate or API, as the analyst may use whichever software is available at the time of the test. There is no adequate reconciliation of all generated electronic test data during the review process for HPLC/GC network equipment.
对实验室电子系统与数据的监督不足。按贵公司的数据复核程序,QC 人员使用经批准的复核程序与检查表,对 HPLC/GC 网络设备的所有分析批记录进行电子检测数据复核。这一复核过程似乎并不充分,因为在该产品的特定复核期间产生的所有可能数据并未全部被复核。例如,贵公司在 HPLC 和 GC 设备上检测中间体与原料药产品,使用了多达五种不同软件,包括 Empower 3、OpenLab CDS、LabSolutions、MassHunter。没有专门用于某一特定中间体或原料药检测的软件,因为分析员检测时可能使用当时可用的任何一套软件。在 HPLC/GC 网络设备的复核过程中,未对所有生成的电子检测数据进行充分核对。
来源:制药经理人 · mp.weixin.qq.com